Benchling, founded in 2012 and based in San Francisco, California, United States, has raised $412 million to date and reached a $6.1 billion valuation after its $100 million Series F round in 2021. The company’s cloud-based bioinformatics platform streamlines biotech R&D with tools for molecular biology design, CRISPR editing, data management, and collaboration. Backed by Fidelity Investments, Lone Pine Capital, and Sequoia Capital, Benchling serves research teams across life sciences and pharmaceutical industries.